Precision for Medicine

The deal joins Precision for Medicine's suite of biomedical research tools and services with ACT Oncology's expertise in clinical study design and execution.

PATH is designed to help users combine and use clinical and genomic information to stratify patients as part of efforts to develop more tailored therapies.

CEOs at four of the five leading mass spec firms saw their total compensation dip last year, according to information provided in their proxy statements, with Bill Sullivan at Agilent taking the biggest hit, a 39 percent drop from his 2007 earnings. Meanwhile, Frank Laukien at Bruker received an 80 percent upgrade in 2008.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.